Pattern Pharma Inc.

Profile

Pattern Pharma’s patent-protected immunotherapeutic, PPI-100, mobilizes innate immunity by targeting TLR4, in order to address cancers and infectious diseases. PPI-100 activates innate immune cells, increasing antigen-presenting activities directed at tumor antigens and resulting in anti-cancer cytotoxic T-cells and long-term T-cell memory. Pattern's initial focus is on a large, white-space opportunity to address the >40% relapse rate in cancer patients 5 years after surgery. Pattern collaborates with MD Anderson, Harvard, McGill and the University of Toronto.

pattern pharma inc.

Website

patternpharma.com

Contact


Event details

Date: January 13 - 15, 2025

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

21 in total